Advanced Pancreatic Ductal Adenocarcinoma (DBCOND0082083)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06585488	A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplification	Cetuximab Tislelizumab	treatment	1	not_yet_recruiting
NCT04887805	Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer	Lenvatinib Pembrolizumab	treatment	2	recruiting
NCT05149326	KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.	Erfonrilimab	treatment	3	active_not_recruiting
NCT05632328	AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC	Botensilimab Gemcitabine Paclitaxel	treatment	2	recruiting
NCT02921022	Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma	Gemcitabine Paclitaxel Pegvorhyaluronidase alfa	treatment	Not Available	active_not_recruiting
NCT06206876	FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma	No drug interventions	treatment	1	not_yet_recruiting